Pembrolizumab plus High-Dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-Year Survival Outcomes and Molecular Signatures from a Phase 2 Trial - Beyond the Abstract
Because of this, patients frequently ask when they might be able to take a treatment holiday. This study presents long-term survival and follow-up of a fixed-duration regimen of pembrolizumab in combination with interleukin-2 (IL-2), administered over 36 weeks, in patients with advanced or metastatic clear cell RCC, contrasting prolonged or indefinite treatment that is currently standard.
While IL-2 has largely fallen out of favor in the modern treatment landscape, it remains familiar to more seasoned oncologists, albeit with a reputation for significant acute toxicity. Its administration typically necessitates inpatient care, representing a stark contrast to the outpatient convenience of modern regimens. This study reframes that tradeoff: acute, time-limited toxicity versus the cumulative burden of indefinite therapy. Notably, toxicity with this regimen was manageable using a five-in-a-row dosing strategy, and at a median follow-up exceeding six years, 42 percent of patients are without the need for further treatment and without persistent grade 2 or higher treatment-related adverse events. With median overall survival not yet reached beyond 84 months, these findings underscore the potential for durable disease control without continuous therapy or significant long-term toxicity.
Beyond clinical outcomes, the study provides exploratory correlative analyses aimed at elucidating the immunologic interplay between checkpoint inhibition and cytokine therapy. Using peripheral blood sampling, the investigators employed transcriptomic approaches using NanoString, proteomic approaches using Olink, and flow cytometry. While limited by the use of peripheral rather than tumor-based samples, the data suggest biologically plausible synergy, including enrichment of CD16-positive natural killer cells, suppression of PD-1-positive T-cells, and coordinated activation of chemokine, complement, and PKC and TGF-beta signaling pathways. These findings, though hypothesis-generating, offer a glimpse into mechanisms that may produce the observed durability of response.
Interpretation of these results must be tempered by the study’s limitations. This was a small, single-center phase II trial involving just 26 patients, and cross-trial comparisons are inherently fraught. Nonetheless, the magnitude and durability of survival outcomes are difficult to ignore and justify further investigation. While further investigation is justified, practical challenges remain as barriers to such investigation. The delivery of IL-2 requires specialized infrastructure and expertise, limiting broader applicability to centers with experience in high-dose cytokine therapy or tumor-infiltrating lymphocyte programs. Furthermore, as a therapy first approved in the 1990s, IL-2 lacks strong financial incentives for industry-driven development. However, next-generation strategies, including masked IL-2 constructs and bispecific platforms incorporating IL-2 with checkpoint blockade, may offer a path forward, aiming to preserve immunologic synergy while mitigating toxicity and logistical barriers.
In an era dominated by continuous therapy, this study revisits an important question: can finite, immunologically potent treatment induce durable survival without the need for indefinite therapy? These data suggest that for a subset of patients, the answer may indeed be yes.
Written by: Jeff Johnson, MD, Hematology Oncology Fellow, Moffitt Cancer Center, Tampa, FL
Read the Abstract